Sign in
ATXS Stock Price, Chart, Stats & News
Astria Therapeutics, Inc.
Save
718.13M
Market cap
–
Current P/E
–
Forward P/E
ATXS chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 100.00% |
Operating margin | -19335.69% |
Pretax margin | -17567.99% |
Net margin | -17567.99% |
Effective tax rate | – |
ROA | -45.62% |
ROE | -45.01% |
D/E | 0.02x |
Interest coverage ratio | – |
ATXS valuation
P/E | – |
P/S | 1017.18x |
P/B | 3.13x |
P/CF | -6.09x |
P/FCF | -5.97x |
P/OCF | -6.09x |
PEG | 1.00x |
EV multiple | -6.04x |
About
Astria Therapeutics, Inc. is a biopharmaceutical company based in Boston, Massachusetts, established in 2008. The firm specializes in identifying, advancing, and bringing to market treatments for uncommon and specialized allergic and immunological disorders across the United States. Its leading experimental drug, STAR-0215, is a monoclonal antibody that targets and inhibits plasma kallikrein.
Similar securities
Based on sector and market capitalization
Report issue